Technology ID
TAB-4846
Advancements in Live Attenuated Vaccines: A Novel Approach for Japanese Encephalitis and Beyond
E-Numbers
E-031-2012-0
Lead Inventor
Whitehead, Stephen
Lead IC
NIAID
Co-Inventors
Gromowski, Gregory
ICs
NIAID
Applications
Therapeutics
Diagnostics
Therapeutic Areas
Infectious Disease
Development Stages
Clinical Phase I
Research Products
Plasmids/Vectors
Antibodies
Animal Models
The development of live attenuated vaccines for Japanese encephalitis (JE) represents a groundbreaking technology with the potential to transform vaccination approaches. These vaccines offer the advantage of single-dose administration, simplifying vaccination schedules and reducing logistical challenges. In addition to their potential cost-effectiveness and accessibility, combining live attenuated JEV vaccines with existing dengue vaccines could provide a comprehensive solution for regions facing the dual threat of JE and dengue viruses, marking a significant advancement in public health strategies.
Commercial Applications
The potential applications of live attenuated vaccines for Japanese encephalitis (JE) extend beyond just this disease. These innovative vaccines, with their single-dose convenience and cost-effectiveness, could serve as a model for combating other viral infections. Furthermore, their adaptability for combining with existing vaccines opens up possibilities for creating multifaceted immunization solutions against various vector-borne diseases, addressing critical public health challenges in diverse regions.
Competitive Advantages
The competitive advantages of live attenuated Japanese encephalitis (JE) vaccines include single-dose administration, cost-effectiveness, improved accessibility, and the potential for combined protection against other vector-borne diseases, enhancing overall public health strategies.
Licensing Contact: